Loading
Device Usage / Colorectal Carcinoma / Breast Carcinoma · Interventional Study
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered feasibility study planned to evaluate the operational and logistical aspects of multi-cancer detection testing in a future definitive RCT. No results are yet reported in this registry record. The study will assess enrollment, follow-up completion, blood sample collection, and loss to follow-up as preliminary evidence to guide design of a larger clinical trial.
Interventional, Randomized, Parallel, Single masking, Screening purpose. Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm,…; age from 45 Years; to 75 Years; accepts healthy volunteers. Intervention: Arm I (Shield MCD test); Arm II (Avantect MCD test). Compared with: Arm III (Control) — Active Comparator. n = 24,000. 40 sites: United States.
This is a registered feasibility study planned to evaluate the operational and logistical aspects of multi-cancer detection testing in a future definitive RCT. No results are yet reported in this registry record. The study will assess enrollment, follow-up completion, blood sample collection, and loss to follow-up as preliminary evidence to guide design of a larger clinical trial.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This feasibility study will inform whether and how a definitive multi-cancer detection screening trial can be conducted; clinicians should await results before considering incorporation into screening pathways. The findings will guide operational decisions such as enrollment logistics, follow-up retention strategies, and specimen collection procedures for future cancer screening trials.
This is a feasibility registry record for a planned interventional study with no results reported; it describes study design and operational endpoints only, appropriate for preliminary classification of early-phase screening research.
As stated by the source record.
Quoted from the source exactly as published.
This feasibility study will inform whether and how a definitive multi-cancer detection screening trial can be conducted; clinicians should await results before considering incorporation into screening pathways. The findings will guide operational decisions such as enrollment logistics, follow-up retention strategies, and specimen collection procedures for future cancer screening trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06995898). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 24000 participants (ESTIMATED). Conditions: Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma. Interventions: PROCEDURE: Biospecimen Collection; DEVICE: Device Usage; OTHER: Electronic Health Record Review; PROCEDURE: Multi-Cancer Detection Test; PROCEDURE: Multi-Cancer Detection Test; OTHER: Questionnaire Administration. Primary outcome measures: Feasibility of enrollment onto study , At time of randomization; Proportion of participants who complete baseline and follow-up questionnaires within 60 days of receipt , Up to 3 years; Proportion of participants who provide the required blood sample for year 1 for Multi-Cancer Detection (MCD) testing within 90 days of recommended time point , Up to 2 years; Proportion of participants considered lost to follow-up within 2 years of randomization , Up to 2 years; Representative enrollment , Up to 2 years; Staggered start of intervention arm 2 , Up to 1 year. Brief summary: The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.